279 related articles for article (PubMed ID: 30593516)
21. Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
Liu S; Duan X; Xu L; Ye J; Cheng Y; Liu Q; Zhang H; Zhang S; Zhu S; Li T; Liu Y
Tumour Biol; 2016 Apr; 37(4):4873-81. PubMed ID: 26526577
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
Murthy RK; Raghavendra AS; Hess KR; Fujii T; Lim B; Barcenas CH; Zhang H; Chavez-Mac-Gregor M; Mittendorf EA; Litton JK; Giordano SH; Thompson AM; Valero V; Moulder SL; Tripathy D; Ueno NT
Clin Breast Cancer; 2018 Dec; 18(6):e1283-e1288. PubMed ID: 30077429
[TBL] [Abstract][Full Text] [Related]
23. Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Beitsch P; Whitworth P; Baron P; Rotkis MC; Mislowsky AM; Richards PD; Murray MK; Pellicane JV; Dul CL; Nash CH; Stork-Sloots L; de Snoo F; Untch S; Lee LA
Ann Surg Oncol; 2017 Sep; 24(9):2539-2546. PubMed ID: 28447218
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
25. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
26. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
Echavarria I; Granja M; Bueno C; Lopez-Tarruella S; Peinado P; Sotelo M; Jerez Y; Moreno F; Torres G; Lobo M; Marquez-Rodas I; Del Monte-Millan M; Martín M; García-Saenz JA
Breast Cancer Res Treat; 2017 Feb; 162(1):181-189. PubMed ID: 28040858
[TBL] [Abstract][Full Text] [Related]
27. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
[TBL] [Abstract][Full Text] [Related]
28. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
29. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
30. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
[TBL] [Abstract][Full Text] [Related]
31. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
[TBL] [Abstract][Full Text] [Related]
32. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
van Ramshorst MS; Loo CE; Groen EJ; Winter-Warnars GH; Wesseling J; van Duijnhoven F; Peeters MTV; Sonke GS
Breast Cancer Res Treat; 2017 Jul; 164(1):99-106. PubMed ID: 28432515
[TBL] [Abstract][Full Text] [Related]
33. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
Scaltriti M; Nuciforo P; Bradbury I; Sperinde J; Agbor-Tarh D; Campbell C; Chenna A; Winslow J; Serra V; Parra JL; Prudkin L; Jimenez J; Aura C; Harbeck N; Pusztai L; Ellis C; Eidtmann H; Arribas J; Cortes J; de Azambuja E; Piccart M; Baselga J
Clin Cancer Res; 2015 Feb; 21(3):569-76. PubMed ID: 25467182
[TBL] [Abstract][Full Text] [Related]
34. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Huang L; Chen S; Yang W; Xu B; Huang T; Yang H; Zheng H; Wang Y; Song E; Zhang J; Cui S; Pang D; Tang L; Lei Y; Geng C; Shao Z
Oncotarget; 2015 Jul; 6(21):18683-92. PubMed ID: 26084292
[TBL] [Abstract][Full Text] [Related]
36. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
38. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
[No Abstract] [Full Text] [Related]
39. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
[TBL] [Abstract][Full Text] [Related]
40. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
